Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts.

Osteoblast-osteoclast coordination is critical in the maintenance of skeletal integrity. The modulation of osteoclastogenesis by immature cells of the osteoblastic lineage is mediated through receptor activator of NF kappa B (RANK), its ligand RANKL, and osteoprotegerin (OPG), a natural decoy receptor for RANKL. Here, the expression of OPG and RANKL in primary mouse osteoblastic cultures was investigated to determine whether the osteoclastogenic stimulus depended on the stage of osteoblastic differentiation and the presence of the calciotrophic hormone 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)). OPG mRNA expression was increased in osteoblastic cultures after the onset of mineralisation relative to less mature cultures, but did not alter in response to 1,25-(OH)(2)D(3) treatment. In contrast, basal RANK L mRNA expression did not change during differentiation but was significantly enhanced by 1,25-(OH)(2)D(3) treatment at all times. The stimulatory effects of 1,25-(OH)(2)D(3) on RANKL were lessened in more mature cultures, however. The RANKL/OPG ratio, an index of osteoclastogenic stimulus, was therefore increased by 1,25-(OH)(2)D(3) treatment at all stages of osteoblastic differentiation, but to a lesser degree in cultures after the onset of mineralisation. Thus the 1,25-(OH)(2)D(3)-driven increase in osteoclastogenic potential of immature osteoblasts appears to be mediated by increased RANKL mRNA expression, with mature osteoblasts having relatively decreased osteoclastogenic activity due to increased OPG mRNA expression. These findings suggest a possible mechanism for the recently proposed negative regulatory role of mature osteoblasts on osteoclastogenesis and indicate that the relative proportions of immature and mature osteoblasts in the local microenvironment may control the degree of resorption at each specific bone site.

[1]  T. Martin,et al.  Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity , 1994, Journal of cellular biochemistry.

[2]  J. Aubin,et al.  Characterization of the 1,25-(OH)2D3-induced inhibition of bone nodule formation in long-term cultures of fetal rat calvaria cells. , 1993, Endocrinology.

[3]  N. Kurihara,et al.  Effect of 1,25-dihydroxyvitamin D3 on alkaline phosphatase activity and collagen synthesis in osteoblastic cells, clone MC3T3-E1. , 1984, Biochemical and biophysical research communications.

[4]  H. Sussman,et al.  Characterization of a human osteoblastic osteosarcoma cell line (SAOS‐2) with high bone alkaline phosphatase activity , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  K. Abromeit Music Received , 2023, Notes.

[6]  D. Lacey,et al.  The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.

[7]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[8]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[9]  E. Ogata,et al.  Stimulation by 1,25-dihydroxyvitamin D3 of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells. , 1991, Bone.

[10]  W. Otto,et al.  Fluorimetric DNA assay for cell growth estimation. , 1992, Analytical biochemistry.

[11]  S. K. Lee,et al.  Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. , 1999, Endocrinology.

[12]  Allan Bradley,et al.  Increased bone formation in osteocalcin-deficient mice , 1996, Nature.

[13]  O. H. Lowry,et al.  The quantitative histochemistry of brain. II. Enzyme measurements. , 1954, The Journal of biological chemistry.

[14]  D. V. Cohn,et al.  Target cells in bone for parathormone and calcitonin are different: enrichment for each cell type by sequential digestion of mouse calvaria and selective adhesion to polymeric surfaces. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[16]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[17]  N. Udagawa,et al.  Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. , 1998, Biochemical and biophysical research communications.

[18]  S. Kaesler,et al.  1,25 Dihydroxyvitamin-D3 Attenuates the Confluence-Dependent Differences in the Osteoblast Characteristic Proteins Alkaline Phosphatase, Procollagen I Peptide, and Osteocalcin , 1999, Calcified Tissue International.

[19]  P. Robey,et al.  Human bone cells in vitro. , 1985, Calcified tissue international.

[20]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[21]  E. Jimi,et al.  Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function. , 1997, Methods in enzymology.

[22]  A. Flanagan,et al.  The role of 1,25-dihydroxycholecalciferol and prostaglandin E2 in the regulation of human osteoclastic bone resorption in vitro. , 1995, International journal of experimental pathology.

[23]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Martin,et al.  Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .

[25]  J. Eisman,et al.  Human and murine osteocalcin gene expression: conserved tissue restricted expression and divergent responses to 1,25-dihydroxyvitamin D3 in vivo. , 1997, Molecular endocrinology.

[26]  N. Nagata,et al.  Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like Cells , 1998 .

[27]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[28]  N. Sato,et al.  Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. , 1999, Biochemical and biophysical research communications.

[29]  T. Martin,et al.  Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. , 1998, Endocrinology.

[30]  S. Reddy,et al.  Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. , 2000, The Journal of clinical investigation.

[31]  Y. Yoshimura,et al.  Effect of extracellular calcium concentrations on osteoclast differentiation in vitro. , 1999, Biochemical and biophysical research communications.

[32]  T. Spelsberg,et al.  Development and characterization of a conditionally immortalized human fetal osteoblastic cell line , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  J. Eisman,et al.  Species-divergent regulation of human and mouse osteocalcin genes by calciotropic hormones. , 2000, Experimental cell research.

[34]  R. Kesterson,et al.  Analysis of Osteocalcin Expression in Transgenic Mice Reveals a Species Difference in Vitamin D Regulation of Mouse and Human Osteocalcin Genes , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  K Yano,et al.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.

[36]  N. Kurihara,et al.  Effect of 1,25-dihydroxyvitamin D3 on alkaline phosphatase activity and collagen synthesis in osteoblastic cells, clone MC3T3-El1 , 1984 .

[37]  G. Stein,et al.  Progressive development of the rat osteoblast phenotype in vitro: Reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix , 1990, Journal of cellular physiology.

[38]  D. Lacey,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in , 2022 .

[39]  N. Udagawa,et al.  A novel molecular mechanism modulating osteoclast differentiation and function. , 1999, Bone.

[40]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Gundberg,et al.  Development and validation of a radioimmunoassay for mouse osteocalcin: paradoxical response in the Hyp mouse. , 1992, Endocrinology.

[42]  Yongwon Choi,et al.  Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Y. Deyama,et al.  Osteoblast maturation suppressed osteoclastogenesis in coculture with bone marrow cells. , 2000, Biochemical and biophysical research communications.

[44]  P. Härkönen,et al.  Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. , 1998, Bone.

[45]  T. Katagiri,et al.  Subcloning of three osteoblastic cell lines with distinct differentiation phenotypes from the mouse osteoblastic cell line KS-4. , 1996, Bone.

[46]  C. Devlin,et al.  The effects of dexamethasone and 1,25-dihydroxyvitamin D3 on osteogenic differentiation of human marrow stromal cells in vitro. , 1994, Archives of oral biology.

[47]  W. Wilfinger,et al.  Fluorometric quantification of DNA in cells and tissue. , 1983, Analytical biochemistry.

[48]  G S Stein,et al.  Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. , 1993, Endocrine reviews.

[49]  T. Martin,et al.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.

[50]  B. Frenkel,et al.  Species-specific glucocorticoid and 1,25-dihydroxyvitamin D responsiveness in mouse MC3T3-E1 osteoblasts: dexamethasone inhibits osteoblast differentiation and vitamin D down-regulates osteocalcin gene expression. , 1997, Endocrinology.

[51]  Y. Deyama,et al.  Low calcium environment effects osteoprotegerin ligand/osteoclast differentiation factor. , 2000, Biochemical and biophysical research communications.

[52]  Rui Zhang,et al.  1,25-Dihydroxyvitamin D3 Inhibits Osteocalcin Expression in Mouse through an Indirect Mechanism* , 1997, The Journal of Biological Chemistry.